European Journal of Rheumatology

Volume 7 • Supplement 3 • October 2020

Systemic sclerosis: A special issue from the European Journal of Rheumatology

- EC/EPC in SSc pathogenesis
- Epigenetic and scleroderma
- Mesenchymal transitions in systemic sclerosis
- Adipokines in systemic sclerosis
- Omics of systemic sclerosis
- Pathogenic autoantibodies in SSc
- Screening for PAH in systemic sclerosis
- Biomarkers in systemic sclerosis
- Cardiac imaging in SSc
- Imaging of Raynaud’s
- SSc subsets
- GI microbiome in systemic sclerosis
- Cyclophosphamide in systemic sclerosis
- News and failures - recent treatment trials in SSc

eurjrheumatol.org
## European Journal of Rheumatology

### Editor in Chief
George C. Tsokos
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

### Guest Editors
Francesco Del Galdo
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Marco Matucci-Cerinic
Division of Rheumatology AOUC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

### Associate Editors
Xenofon Baraliakos
Department of Rheumatology, Ruhr-University Bochum, Bochum, Germany

Hector Corominas
Servei de Reumatologia, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain

Guo-Min Deng
Department of Rheumatology, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Christian Hedrich
Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool School of Life Sciences, Liverpool, UK. Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, UK

Bünyamin Kısacık
Department of Rheumatology, Gaziantep Medical Park Hospital, Gaziantep, Turkey

Seung-Ki Kwok
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea

Vasileios C. Kyttaridis
Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

Roger A. Levy
Department of Rheumatology, The State University of Rio de Janeiro, Rio De Janeiro, Brazil

Stmatis-Nick Liosis
Division of Rheumatology, University of Patras School of Medicine, Patras University Hospital, Patras, Greece

Pierre Miossec
Department of Immunology and Rheumatology, Edouard Herriot Hospital, Lyon, France

Ahmet Mesut Onat
Department of Rheumatology, Gaziantep Medical Park Hospital, Gaziantep, Turkey

Carlo Perricione
Rheumatology, Dipartimento di Medicina, University of Perugia, Perugia, Umbria, Italy

Amir H. Sawalha
Department of Pediatrics, Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA

Amir Sharabi
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Clinical Immunology, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel

Yusuf Yazıcı
NYU Hospital for Joint Diseases, New York, NY USA

### Statistical Editor
İsmail Sani
Department of Rheumatology, Dokuz Eylül University School of Medicine, Izmir, Turkey

### Owner and Responsible Manager
Ahmet Mesut Onat
Professor in Rheumatology

Publisher
İbrahim KARA

Publication Director
Ali ŞAHİN

Editorial Development
Gizem KAYAN TEKAYUT

Deputy Publication Director
Gökhan ÇİMEN

Publication Coordinators
İrem SOYSAL
Aziz YILDIRIM
Deniz KAYA
Bahar ALBAYRAK
Emre KARA
Zeynep YARŞİRER UREN
Beyzanur KARABULUT

Project Coordinators
Sinem Fehime KOZ
Doğan ORUÇ

Graphics Department
Unal OZER
Deniz Elif DURAN
Beyzanur KARABULUT

Contact
Address: Büyükdere Cad. No: 105/9 34394 Mecidiyeköy, Şişli, İstanbul
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
E-mail: info@avesyayincilik.com
AIMS AND SCOPE

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The aim of the European Journal of Rheumatology is to cover various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case based reviews, letters to the editor and images in rheumatology. The publication language of the journal is English.

The journal's target audience includes academicians, practitioners, specialists and students from all disciplines of rheumatology.

European Journal of Rheumatology adheres to the principles outlined by the guidelines of ICMJE, WAME, EASE and COPE.

European Journal of Rheumatology is currently indexed in PubMed Central, Web of Science-Emerging Sources Citation Index, EBSCO and CINAHL.

All published content of the European Journal of Rheumatology is available online at eurjrheumatol.org, free of charge.

Statements or opinions expressed in the manuscripts published in the European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

European Journal of Rheumatology is an open access publication and the journal's publication model is based on Budapest Open Access Initiative (BOAI) declaration. Journal's archive is available online, free of charge at eurjrheumatol.org. European Journal of Rheumatology content is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The journal is printed on an acid-free paper.

Reprint requests and requests concerning advertising should be addressed to the publisher;

Address: Büyükdere Cad. 105/9 34394 Mecidiyeköy, Şişli, İstanbul, Turkey
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
e-mail: info@avesyayincilik.com
avesyayincilik.com
European Journal of Rheumatology (Eur J Rheumatol) is an international, open access, peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The journal covers various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, auto-inflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology. The publication language of the journal is English.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Manuscripts submitted to European Journal of Rheumatology will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors’ responsibility to carefully protect the patients’ anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

All submissions are screened by a similarity detection software (iThenticate by CrossCheck).

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

European Journal of Rheumatology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through www.eurjrheumatol.org during the initial submission process in order to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of “gift authorship,” the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding
EJR
European Journal of Rheumatology

author should also send a short statement declaring that he/she accepts to undertake all the responsibility for authorship during the submission and review stages of the manuscript.

European Journal of Rheumatology requires and encourages the authors and the individuals involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors. Cases of a potential conflict of interest of the editors, authors, or reviewers are resolved by the journal’s Editorial Board within the scope of COPE and ICMJE guidelines.

The Editorial Board of the journal handles all appeal and complaint cases within the scope of COPE guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

European Journal of Rheumatology requires each submission to be accompanied by a Copyright License Agreement (available for download http://www.eurjrheumato.org). When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial, and criminal liabilities in this regard belong to the author(s). By signing the Copyright License Agreement, authors agree that the article, if accepted for publication by the European Journal of Rheumatology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC-BY-NC).

Statements or opinions expressed in the manuscripts published in European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors.

MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2019 - http://www.icmje.org/icmje-recommendations.pdf). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, STARD guidelines for studies on diagnostic accuracy, PRISMA guidelines for systematic reviews and meta-analysis, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behaviour.

Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system, available at www.eurjrheumato.org. Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:
- Copyright Agreement,
- Author Contributions Form, and
- ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors) during the initial submission. These forms are available for download at www.eurjrheumato.org.

Preparation of the Manuscript

Title page: A separate title page should be submitted with all submissions and this page should include:
- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name(s), affiliations, and highest academic degree(s) of the author(s),
- Grant information and detailed information on the other sources of support,
- Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
- Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: An abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Original Articles should be structured with subheadings (Objective, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.

Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).

Main Points: All submissions except letters to the editor and images in rheumatology should be accompanied by 3 to 5 “main points” which should emphasize the most noteworthy results of the study.

...
and underline the principle message that is addressed to the reader. This section should be structured as itemized to give a general overview of the article. Since “Main Points” targeting the experts and specialists of the field, each item should be written as plain and straightforward as possible.

**Manuscript Types**

**Original Articles:** This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Methods, Results, and Discussion subheadings. Please check Table 1 for the limitations for Original Articles.

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983: 7: 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

**Review Articles:** Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

**Case-based Reviews:** Case-based reviews are reports on rare cases or conditions that constitute challenges in diagnosis and treatment, incorporating a mini literature review of a particular area of the field. Please check Table 1 for the limitations for Case-based Reviews.

**Letters to the Editor:** This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers’ attention, particularly educators, may also be submitted in the form of a “Letter to the Editor.” Readers can also present their comments on the published manuscripts in the form of a “Letter to the Editor.” Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

**Images in Rheumatology:** This type of submissions should present a striking image that may challenge and inform readers and contribute to their education. Please check Table 1 for the limitations for Images in Rheumatology.

**Tables**

Tables should be included in the main document, presented after the reference list, and they should be numbered consecutively in the order they are referred to within the main text. A descriptive title must be placed above the tables. Abbreviations used in the tables should be defined below the tables by footnotes (even if they are defined within the main text). Tables should be created using the “insert table” command of the word processing software and they should be arranged clearly to provide easy reading. Data presented in the tables should not be a repetition of the data presented within the main text but should be supporting the main text.

**Figures and Figure Legends**

Figures, graphics, and photographs should be submitted as separate files (in TIFF or JPEG format) through the submission system. The files should not be embedded in a Word document or the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc.) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like the rest of the submission, the figures too should be blind. Any information within the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text.

<table>
<thead>
<tr>
<th>Table 1. Limitations for each manuscript type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of manuscript</strong></td>
</tr>
<tr>
<td>Original Article</td>
</tr>
<tr>
<td>Review Article</td>
</tr>
<tr>
<td>Case-based Reviews</td>
</tr>
<tr>
<td>Letter to the Editor</td>
</tr>
<tr>
<td>Images in Rheumatology</td>
</tr>
</tbody>
</table>
The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: ‘‘Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA).’’ All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

References
While citing publications, preference should be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided. Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/ MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first six authors should be listed followed by ‘‘et al.’’ In the main text of the manuscript, references should be cited using Arabic numbers in parentheses. The reference styles for different types of publications are presented in the following examples.


Editor(s) as Author: Huizing EH, de Groot JAM, editors. Functional reconstructive nasal surgery. Stuttgart-New York: Thieme; 2003.


REVISIONS
When submitting a revised version of a paper, the author must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal’s webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof.

Editor in Chief: George C. Tsokos
Address: Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Phone: -
E-mail: editorialoffice@eurjrheumatol.org
Publisher: Ahmet Mesut Onat
CONTENTS

**Editorial**

S137  
A special European Journal of Rheumatology issue on systemic sclerosis: What and why?  
Francesco Del Galdo, Marco Matucci-Cerinic

**Invited Reviews**

S139  
Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis  
Yuko Ota, Masataka Kuwana

S147  
Epigenetics and systemic sclerosis: An answer to disease onset and evolution?  
Ahmad Ramahi, Nezam Altorok, Bashar Kahaleh

S157  
The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis  
Irene Rosa, Eloisa Romano, Bianca Saveria Fioretto, Mirko Manetti

S165  
Role of adipokines in systemic sclerosis pathogenesis  
Klaus W. Frommer, Elena Neumann, Ulf Müller-Ladner

S173  
Molecular “omic” signatures in systemic sclerosis  
Bhaven K. Mehta, Monica E. Espinoza, Monique Hinchcliff, Michael L. Whitfield

S181  
Putative functional pathogenic autoantibodies in systemic sclerosis  
Devis Benfaremo, Silvia Svegliati Baroni, Lucia Manfredi, Gianluca Moroncini, Armando Gabrielli

S187  
Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!  
Zoe R. Brown, Mandana Nikpour

S193  
Biomarkers as an opportunity to stratify for outcome in systemic sclerosis  
Giuseppina Abignano, Francesco Del Galdo

S203  
The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making  
Sophie I. Mavrogeni, Maya Buch, George Markouisis-Mavrogenis, Bianca Dumitrut, Nicola Riccardo Pugliese, Luna Gargani

S212  
New perspectives in the imaging of Raynaud’s phenomenon  
Ariane L. Herrick, Graham Dinsdale, Andrea Murray

S222  
Systemic sclerosis: To subset or not to subset, that is the question  
Sindhu R. Johnson, Frank van den Hoogen, Keshini Devakandan, Marco Matucci-Cerinic, Janet E. Pope

S228  
Gastrointestinal tract microbiota modifications in systemic sclerosis  
Elizabeth R. Volkman, Anna-Maria Hoffmann-Vold

S237  
The burning question: To use or not to use cyclophosphamide in systemic sclerosis  
Cosimo Bruni, Daniel E. Furst

S242  
News and failures from recent treatment trials in systemic sclerosis  
Christopher P. Denton, Philip Yee, Voon H. Ong